Clinical Trial Update: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating pramlintide (Symlin) for treating hypoglycemia after gastric bypass surgery has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• After Gastric Bypass Surgery Complications
• Gastrectomy-related Hypoglycemia
• Hypoglycemia

Drugs mentioned

• pramlintide (pramlintide)

Snippet

Sponsor: Joslin Diabetes Center | Conditions: Hypoglycemia, Evidence of Previous Gastric Surgery | Phase 4 | Status: COMPLETED | Results posted: 2022-05-26